Current and future therapeutic options for the management of gout

Andrew Whelton

Research output: Contribution to journalArticle

Abstract

The incidence of gout and the clinical manifestation of hyperuricemia continue to rise. In addition to painful acute attacks, chronic gout can lead to the development of crystal arthropathy, tophi, and renal lithiasis, coincidental with declines in quality of life. As a greater appreciation for the associations between hyperuricemia, gout, and certain comorbidities, such as renal impairment and cardiovascular diseases, grows, so does the search for new therapeutic options to both alleviate the painful symptoms of acute gout attacks and reduce the underlying hyperuricemia. This manuscript reviews the pathophysiology of hyperuricemia and gout, and associated comorbidities, and then discusses traditional therapeutic options, newly available agents, and future targets for pharmacologic management.

Original languageEnglish (US)
Pages (from-to)402-417
Number of pages16
JournalAmerican Journal of Therapeutics
Volume17
Issue number4
DOIs
StatePublished - Jul 2010

Keywords

  • febuxostat
  • gout
  • hyperuricemia
  • uricase

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Medicine(all)

Fingerprint Dive into the research topics of 'Current and future therapeutic options for the management of gout'. Together they form a unique fingerprint.

  • Cite this